Eric Topol, MD GLP-1s seem are showing so much promise in a variety of diseases that it is exciting what such sparks of innovation that will be future developed from GLP-1 to mitigate some of our biggest healthcare challenges
Medicines with a narrow therapeutic index may require additional monitoring, and warfarin may require more frequent INR monitoring when initiating GLP-1 therapy
Further Reading EU Investigates Ozempic Maker After Reports Of Suicidal Thoughts (Forbes) Wegovy Shortage: Drug Maker Limits DistributionHeres When Supplies Should Improve (Forbes)
Access this chapter Subscribe and save Buy Now Tax calculation will be finalised at checkout Purchases are for personal use only Similar content being viewed by others References Agouridas V, El Mahdi O, Diemer V, Cargot M, Monbaliu JCM, Melnyk O (2019) Native chemical ligation and extended methods: mechanisms, catalysis, scope, and limitations